Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Models of Selective Insulin Resistance: Alpelisib, Part I
NCT06354088Phase 1Recruiting
- Sponsor
- Columbia University
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alpelisib in insulin resistance (IR), prediabetes, Overweight and 2 more (4 arms), sponsored by Columbia University. Primary endpoints: Hepatic de novo lipogenesis at 24 hours and Endogenous glucose production at 15 hours. Started Apr 2024; status: recruiting.
02
Drugs
alpelisib
03
Conditions
insulin resistance (IR)prediabetesOverweightobesitynon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06354088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354088.